Deep Apple Therapeutics and Novo Nordisk entered a collaboration valued up to $812 million to develop small molecule therapies targeting non-incretin GPCRs for cardiometabolic diseases, including obesity. Deep Apple’s AI-driven platform supports target discovery while Novo oversees development and commercialization. This partnership exemplifies increasing integration of AI technologies in drug development to accelerate pipeline diversification.